GlassScriptPhysician profile
Ellen A Ronnen
NPI 1003828823
$3,398.66
in general payments reported to CMS, 2019-2025
24 companies · $149 in 2025
The $149 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $81.84 · 2020: $12.45 · 2021: $1,887 · 2022: $473 · 2023: $557 · 2024: $239 · 2025: $149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $944.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $944.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $1,875.00 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $162.35 | 2023-2025 | Opdivo, Opdualag, Krazati |
| Daiichi Sankyo INC. | $154.21 | 2022-2024 | Enhertu |
| Exelixis INC. | $146.81 | 2022-2024 | Cabometyx |
| Karyopharm Therapeutics INC. | $137.44 | 2020-2023 | Xpovio |
| Pfizer INC. | $125.02 | 2019-2025 | |
| Epizyme, INC. | $125.00 | 2022 | |
| Amgen INC. | $103.78 | 2019-2022 | |
| Blueprint Medicines Corporation | $93.47 | 2023 | Ayvakit |
| Celgene Corporation | $72.20 | 2023-2025 | Reblozyl |
| Abbvie INC. | $66.73 | 2019-2025 | Venclexta |
| Gilead Sciences, INC. | $52.03 | 2021-2025 | Trodelvy |
| Mirati Therapeutics, INC. | $42.45 | 2023-2024 | Krazati |
| Astellas Pharma US INC | $38.47 | 2023-2025 | Padcev, Xospata |
| Ipsen Biopharmaceuticals, INC | $35.79 | 2024-2025 | Onivyde, Somatuline Depot |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Octapharma USA, INC. | $32.23 | 2024 | Panzyga, Octagam Immune Globulin (Human) |
| Sirtex Medical INC | $21.68 | 2019 | |
| Adc Therapeutics America, INC. | $21.18 | 2023 | |
| Verastem, INC. | $20.13 | 2019 | |
| Glaxosmithkline, LLC. | $19.05 | 2024 | Ojjaara |
| Novartis Pharmaceuticals Corporation | $18.75 | 2023 | |
| Stemline Therapeutics INC. | $18.52 | 2024 | Orserdu |
| Genentech USA, INC. | $16.37 | 2023 | Venclexta |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$54,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ellen Ronnen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.